Natural product inhibitors and activators of histone deacetylases

Bioactive Natural Products: Opportunities and Challenges in Medicinal Chemistry

Volumn , Issue , 2011, Pages 273-309

  Scott, Michael D ^a   Haldar, Manas K ^a   Mallik, Sanku ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84973098864     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789814335386_0004     Document Type: Chapter

References (104)

1. Vigushin DM, Coombes RC. (2004) Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets 4: 205-218.
2. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. (1999) Structures of a histone deacetylase homo-logue bound to the TSA and SAHA inhibitors. Nature 40: 188-193.
3. Terui T, Murakami K, Takimoto R, Takahashi M, Takada K, Murakami T, Minami S, Matsunaga T, Takayama T, Kato J, Niitsu Y. (2003) Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res 63: 8948-8954.
4. Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM, La Quaglia MP. (1999) Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 59: 4392-4399.
5. Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee YW, Lee HW, Han JW. (2002) Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 277: 2073-2080.
6. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H, Sakai T. (1997) Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 272: 22199-22206.
7. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H, Skai T. (1997) Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241: 142-150.
8. Gui CV, Ngo L, Xu WS, Richon VM, Marks PA. (2004) Histone deacety-lase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101: 1241-1246.
9. Davie JR. (2003) Inhibition of histone deacetylase activity by butyrate. J Nutr 133: 2485S-2493S.
10. Della Ragione F, Criniti V, Della Pietra V, Borriello A, Oliva A, Indaco S, Yamamoto T, Zappia V. (2001) Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett 499: 199-204.
11. Finzer P, Ventz R, Kuntzen C, Seibert N, Soto U, Rosl F. (2002) Growth arrest of HPV-positive cells after histone deacetylase inhibition is independent of E6/E7 oncogene expression. Virology 304: 265-273.
12. Chen Z, Clark S, Birkeland M, Sung CM, Lago A, Liu R, Kirkpatrick R, Johnanson K, Winkler JD, Hu E. (2002) Induction and superinduction of growth arrest and DNA damage gene45(GADD45) alpha and beta messenger RNAs by histone deactylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett 188: 127-140.
13. Hinnebusch BF, Meng S, Wu JT, Archer SY, Hodin RA. (2002) The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr 132: 1012-1017.
14. Davis T, Kennedy C, Chiew YE, Clarke CL, deFaxio A. (2000) Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin Cancer Res 6: 4334-4342.
15. Nair AR, Boersma LJ, Schilz L, Chaudhry MA, Muschel RJ, Chaudry A. (2001) Paradoxical effects of trichostatin A: Inhibition of NF-Y-associated histone acetyltransferase activity, phosphorylation of hGCN5 and down-regulation of cyclin A and B1 mRNA. Cancer Lett 166: 55-64.
16. Van Lint C, Emiliani S, Verdin E. (1996) The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expression 5: 245-253.
17. Bernhard D, Ausserlechner MJ, Tonko M, Loffler M, Hartmann BL, Csordas A, Kofler R. (1999) Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. FASEB J 13: 1991-2001.
18. Novogrodsky A, Dvir A, Ravid A, Shkolnik T, Stenzel KH, Rubin AL, Zaizov R. (1983) Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer 51: 9-14.
19. Myzak MC, Dashwood RH. (2006) Histone deacetylases as targets for dietary cancer preventive agents: Lessons learned with butyrate, diallyl disulfide, and sulforaphane. Current Drug Targets 7: 443-452.
20. Wu JT, Archer SY, Hinnebusch B, Meng S, Hodin RA. (2001) Transient vs. prolonged histone hyperacetylation: Effects on colon cancer cell growth, differentiation, and apoptosis. Am J Physiol Gastrointest Liver Physiol 280: G482-G490.
21. Emenaker NJ, Calaf GM, Cox D, Basson MD, Qureshi N. (2001) Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, BAX, p21 and PCNA protein expression in an in vitro cell culture model. JNutr 131: 3041S-3046S.
22. Li X, Mikkelsen IM, Mortensen B, Winberg JO, Huseby NE. (2004) Butyrate reduces liver metastasis of rat colon carcinoma cells in vivo and resistance to oxidative stress in vivo. Clin Exp Metastasis 21: 331-338.
23. Johnstone RW. (2002) Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299.
24. Guyonnet D, Berges R, Siess MH, Pinnert MF, Chagnon MC, Suschetet M, Le Bon AM. (2004) Post-initiation modulating effects of allyl sulfides in rat hepatocarcinogenesis. Food Chem Toxicol 42: 1479-1485.
25. Lea MA, Randolph VM, Patel M. (1999) Increased acetylation of histones induced by diallyl disulfide and structurally related molecules. Int J Oncol 15: 347-352.
26. Lea MA, Randolph VM. (2001) Induction of histone acetylation in rat liver and hepatoma by organosulfur compounds including diallyl disulfide. Anticancer Res 21: 2841-2845.
27. Ho E, Clarke JD, Dashwood RH. (2009) Dietary Sulforaphane, a histone deacetylase inhibitor for cancer prevention. J Nutr 139: 2393-2396.
28. Druesne N, Pagniez A, Mayeur C, Thomas M, Cherbuy C, Duee PH, Martel P, Chaumontet C. (2004) Dially disulfide (DADS) increase histone acetylation and p21/waf1/cip1 expression in human colon tumor cell lines. Carcinogenesis 25: 1227-1236.
29. Lea MA, Rasheed M, Randolph VM, Khan F, Shareef A, desBordes C. (2002) Induction of histone acetylation and inhibition of growth of mouse erythroleukemai cells by S-allylmercaptocysteine. Nutr Cancer 43: 90-102.
30. Bontempo P, Milta L, Miceli M, Doto A, Nebbioso A, De Bellis F, Conte M, Minichiello A, Manzo F, Carafa V, Basile A, Rigano D, Sorbo S, Cobianchi RC, Schiavone EM, Ferrara F, De Simone M, Vietri MT, Cioffi M, Sica V, Bresciani F, de Lera AR, Altucci L, Molinari AM. (2007) Feijoa sellowiana derived natural flavone exerts anti-cancer action displaying HDAC inhibitory activities. Int J Biochem Cell Biol 39: 1902-1914.
31. Bouchain G, Delorme D. (2003) Novel hydrozmate and anilide derivatives as potent histone deacetylase inhibitors: Synthesis and antiproliferative evaluation. Curr Med Chem 10: 2359-2372.
32. Amin A, Gali-Muhtasib H, Ocker M, Schneider-Stock R. (2009) Overview of major classes of plant-derived anticancer drugs. Int J Biomed Sci 5: 1-11.
33. Svasti J, Srisomsap C, Subhasitanont P, Keeratichamroen S, Chokchaichamnankit D, Ngiwsara L, Chimnoi N, Pisutjaroenpong S, Techasakul S, Chen ST. (2005) Proteomic profiling of cholangiocarcinoma cell line treated with pomiferin from Derris maclaccensis. Proteomics 5: 4504-4509.
34. Tsao R, Yang R, Young JC. (2003) Antioxidant isoflavones in Osage orange, Maclura pomifera (Raf.) Schneid. J Agric Food Chem 51: 6445-6451.
35. Mahmoud ZF. (1981) Antimicrobial components from Maclura pomifera fruit. Planta Med 42: 299-301.
36. Son IH, Chung IM, Lee SI, Yang HD, Moon HI. (2007) Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera. Bioorg Med Chem Lett 17: 4753-4755.
37. Chung IL, Conaway CC, Rao CV, Reddy BS. (2000) Chemoprevention of colonic aberrant crypt foci in Fisher rats by sulfroraphane and phenethyl isothiocyanate. Carcinogenesis 21: 2287-2291.
38. Fahey JW, Zhang Y, Talalay P. (1997) Broccoli sprouts: An exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci USA 94: 10367-10372.
39. Zhang Y, Callaway EC. (2002) High cellular accumulation of sulphoraphane, a dietary anticarcinogen, is followed by rapid transporter-mediated export as a glutathione conjugate. Biochem J 364: 301-307.
40. Kassahun K, Davis M, Hu P, Martin B, Baillie T. (1997) Biotransformation of the naturally occurring isothiocyante sulforaphane in the rat: Identification of phase I metabolities and glutathione conjugates. Chem Res Toxicol 10: 1228-1233.
41. Myzak MC, Karplus PA, Chung FL, Dashwood RH. (2004) A novel mechanism of chemoprotection by sulforaphane: Inhibition of histone deacetylase. Cancer Res 64: 5767-5774.
42. Anwar-Mohamed A, El-Kadi, AOS. (2009) Sulforaphanc induces CYP1A1 mRNA, protein, and catalytic activity levels via an AhR-dependant pathway in murine hepatoma Hepa Iclc7 and human Hep62 cells. Cancer Lett 275: 93-101.
43. Nian H, Delage B, Ho E, Dashwood RH. (2009) Modulation of histone deacetylase activity by dietary isothio-cyanates and allyl sulfides: Studies with sulforaphane and garlic organosulfur compounds. Environ Mol Mutagen 50: 213-221.
44. Pledgie-Tracy A, Sobolewski MD, Davidson NE. (2007) Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther 6: 1013-1021.
45. Matsui TA, Murata H, Sakabe T, Sowa Y, Horie N, Nakanishi R, Sakai T, Kubo T. (2007) Sulforaphane induces cell cycle arrest and apoptosis in murine osteosarcoma cells in vitro and inhibits tumor growth in vivo. Oncol Rep 18: 1263-1268.
46. Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E. (2007) Sulforaphane retards the growth of human PC-3 xenographs and inhibits HDAC activity in human subjects. Exp Biol Med 232: 227-234.
47. Singh AV, Xiao D, Lew KL, Dhir R, Singh SV. (2004) Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis 25: 83-90.
48. Zhang Y, Kensler TW, Cho CG, Posner GH, Tallalay P. (1994) Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci USA 91: 3147-3150.
49. Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood, RH. (2006) Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorige-nesis in Apc-minus mice. FASEB J 20: 506-8.
50. Nakao Y, Yoshida S, Matsunaga S, Shindoh N, Terada Y, Nagai K, Yamashita JK, Ganesan A, van Soest RWM, Fusetani N. (2006) Azumamides A-E: Histone deacetylase inhibitory cyclic tetrapeptides from the marine spong Mycale izuensis. Angew Chem Int Ed 45: 7553-7557.
51. Shemyakin MM, Ovchinnikov YA, Ivanov VT. (1969) Topochemical investigations on peptide systems. Angew Chem Int Ed 8: 492-499.
52. Prelog IV, Gerlach H. (1964) Cycloenantiomerism, and cyclodias-teromerism. Helv Chim Acta 47: 2288-2294.
53. Goodman M, Chorev M. (1979) On the concept of linear modified retro-peptide structures. Acc Chem Res 12: 1-7.
54. Maulucci N, Chini MC, Di Micco S, Izzo I, Cafaro E, Russo A, Gallinari P, Paolini C, Nardi MC, Casapullo A, Riccio R, Bifulco G De Riccardis F. (2007) Molecular insights into azumamide E histone deacetylases inhibitory activity. J Am Chem Soc 129: 3007-3012.
55. Colletti SL, Myers RW, Darkin-Rattray SJ, Gurnett AM, Dulski PM, Galuska S, Allocco JJ, Ayer MB, Li C, Lim J, Crumley TM, Cannova C, Schmatz DM, Wyvratt MJ, Fisher MH, Meinke PT. (2001) Broad spectrum antiprotozoal agents that inhibit histone deacetylase: Structure-activity relationships of apicidin. Part 2. Bioorg Med Chem Lett 11: 113-117.
56. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. (2001) Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA 98: 87-92.
57. Kim SD. (1995) Relationships between structural features and biological activities of HC-toxin. J Biochem Mol Biol 28: 227-231.
58. Fusetani N, Asai N, Matsunaga S, Honda K, Yasumuro K. (1994) Bioactive marine metabolities. 59. Cyclostellettamines A-F, pyridine alkaloids which inhibit binding of methyl quinuclidinyl benzylate (QNB) to muscarinic acetylcholine receptors, from the marine sponge, Stelletta maxima. Tetrahedron Lett 35: 3967-3970.
59. Oku N, Nagai K, Shindoh N, Terada Y, Van Soest RWM, Matsunaga S, Fusetani N. (2004) Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Biorg Med Chem Lett 14: 2617-2620.
60. De Oliveira JHHL, Grube A, Koeck M, Berlinck RGS, Macedo ML, Ferreira AG, Hajdu E. (2004) Ingenamine G and cyclostellettamines G-I, K, and L from the new Brazilian species of marine sponge Pachychalina sp. J Nat Prod 67: 1685-1689.
61. Perez-Balado C, Nebbioso A, Rodriguez-Grana P, Minichiello A, Miceli M, Altucci L, de Lera AR. (2007) Bispyridinium dienes: Histone deacetylase inhibitors with selective activities. J Med Chem 50: 2497-2505.
62. Quinoa E, Crews P. (1987) Phenolic constituent of Psammaplysilla Tetrahedron Lett 28: 3229-3232.
63. Ahn MY, Jung JH, Na YJ, Kim HS. (2008) A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol Oncol 108: 27-33.
64. McCulloch MWB, Coombs GS, Banerjee N, Bugni TS, Cannon KM, Harper MK, Veltri CA, Virshup DM. (2009) Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives. Bioorg Med Chem 17: 2189-2198.
65. Pina IC, Gautschi JT, Wang GYSW, Sanders ML, Schmitz FJ, France D, Cornell-Kennon S, Sambucetti LC, Remiszewski SW, Perex LB, Bair KW, Crews P (2003) Psammaplins from the sponge Pseudoceratina purpurea: Inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem 68: 3866-3873.
66. Singh SB, Zink DL, Liesch JM, Mosley RT, Dombrowski AW, Bills GF, Darkin-Rattray SJ, Schmatz DM, Goetz MA. (2002) Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal a-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities. J Org Chem 67: 815-825.
67. Jones P, Steinkuhler C. (2008) From natural products to small molecule ketone histone deacetylase inhibitors: Development of new class specific agents. Curr Pharm Des 14: 545-561.
68. Closse A, Hugenin R. (1974) Isolation and structural clarification of chlamydocin. Helv Chim Acta 57: 533-545.
69. Shivashimpi GM, Amagai S, Kato T, Nishino N, Maeda S, Nishino TG, Yoshida M. (2007) Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem 15: 7830-7839.
70. Nishino N, Jose B, Shinta R, Kato T, Komatsu Y, Yoshida M. (2004) Chlamydocin-hydroxamic acid analogues as histone deacetylase inhibitors. Bioorg Med Chem 12: 5777-5784.
71. Bhuiyan MPI, Kato T, Okauchi T, Nishino N, Mueda S, Nishino TG, Yoshida M. (2006) Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. Bioorg Med Chem Lett 14: 3438-3446.
72. Mori H, Urano Y, Abe F, Furukawa S, Tsurumi Y, Sakamoto K, Hashimoto M, Takase S, Hino M, Fujii T. (2003) FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits ammalian histone deacetylase (HDAC). I. Taxonomy, fermentation, isolation and biological activities. J Antibiot 56: 72-79.
73. Bougdour A, Maubon D, Baldacci P, Ortet P, Bastien O, Bouillon A, Barale JC, Pelloux H, Menard R, Hakimi MA. (2009) Drug inhibition of HDAC3 and epigenetic control of differentiation in apicomplexa parasites. J Exper Med 206: 953-966.
74. Brosch G, Ransom R, Lechner T, Walton JD, Loidl P. (1995) Inhibition of maize histone deacetylases by HC Toxin, the host-selective toxin of cochliobolus carbonum. Plant Cell 7: 1941-1950.
75. Joung KE, Kim DK, Shenn YY. (2004) Antiproliferative effect of Trichostatin A and HC-Toxin in T47D Human Breast Cancer Cells. Arch Pharm Res 27: 640-645.
76. Deubzer HE, Ehemann V, Kulozik AE, Westermann F, Savelyeva L, Kopp-Schneider A, Riester D, Schwab M, Witt O. (2008) Antineuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro. Cancer Lett 264: 21-28.
77. Nasveschuk CG, Ungermannova D, Liu X, Phillips AJ. (2008) A concise total synthesis of largazole, solution structure, and some preliminary structure activity relationships. Org Lett 10: 3595-3598.
78. Ying Y, Taori K, Kim H, Hong, Luesch H. (2008) Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J Am Chem Soc 130: 8455-8459.
79. Zeng X, Yin B, Hu Z, Liao C, Liu J, Li S, Li Z, Nicklaus MC, Zhou G Jiang S. (2010) Total synthesis and biological evaluation of largazole and derivatives with promising selectivity for cancer cells. Org Lett 12: 1368-1371.
80. Taunton J, Collins JL, Schreiber SL. (1996) Synthesis of natural and modified trapoxins, useful reagents for exploring histone deacetylase function. J Am Chem Soc 118: 10412-10422.
81. Kijima M, Yoshida M, Susita K, Horinouchi S, Beppu T. (1993) Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 30: 22429-22435.
82. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. (2001) Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol S1: S20-S26.
83. Tsuji N, Kobayashi M. (1978) Trichostatin C, a glucopyranosyl hydroxamate. J Antibiot 31: 939-944.
84. Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K. (1976) A new antifungal antibiotic, trichostatin. J Antibiot 29: 1-6.
85. Yoshida M, Iwamoto Y, Uozumi T, Beeppu T. (1985) Trichostatin C, a new inducer of differentiation of friend leukemic cells. Agric Biol Chem 49: 563-565.
86. Yoshida M, Nomura S, Beppu T. (1987) Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res 47: 3688-3691.
87. Yoshida, M, Kijima M, Akita M, Beppu T. (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174-17179.
88. Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG, Schuppan D. (2002) The histone-deacetylase inhibitor trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 36: 233-240.
89. Pujuguet P, Radisky D, Levy D, Lacza C, Bissell MJ. (2001) Trichostatin A inhibits ß-casein expression in mammary epithelial cells. J Cell Biochem 83: 660-670.
90. Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG. (1999) Antitumor activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 80: 1252-1258.
91. Riley K. (2009) FDAApproves Drug treatment for rare cancer Cutaneous T-cell Lymphoma affects about 1,500 Americans annually. FDA News Release (Webpage last assessed on 6/2/2010). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm189629.htm.
92. Furamai R, Matsuyuma A, Kobashi N, Lee KH, Nishiyama N, Nakajima H, Tanka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S. (2002) FK228 Depsipeptide as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62: 4916-4921.
93. Yurek-George A, Cecil ARL, Mo AHK, Wen S, Rogers H, Habens F, Maeda S, Yoshida M, Packham G, Ganesan A. (2007) The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor. J Med Chem 50:5720-5726.
94. Masuoka Y, Nagai A, Shin-ya K, Furihata K, Nagai K, Suzuki K, Hayakawa Y, Seto Y (2001) Spiruchostatins A and B, novel gene expression-enhancing substrances produced by Pseudomonas sp. Tetrahedron Lett 42: 41-44.
95. Yurek-George A, Habens F, Brimmell M, Packham G Ganesan A. (2004) Total synthesis of spiruchostatin A, a potent histone deacetylase inhibitor. JAm Chem Soc 126: 1030-1031.
96. Narita K, Kikuchi T, Watanabe K, Takizawa T, Oguchi T, Kudo K, Matsuhara K, Abe H, Yamori T, Yoshida M, Katoh T. (2009) Total synthesis of the bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5"-epi-spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity. Chem Eur J15: 11174-11186.
97. Barnes PJ. (2009) Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 71: 451-464.
98. Ito K, Ito M, Elliott MW, Cosio B, Carmaori G, Kon OM, Barczyk A, Hayashi S, Adcock LM, Hogg JC, Barnes PJ. (2005) Decreased histone deacetylase activity in chronic obstructive pulmonary disease. New Engl JMed 352: 1957-1976.
99. Osoata G Adcock IM, Barnes PJ, Ito K. (2005) Oxidative stress causes HDAC2 reduction by nitration, ubiquitinylation and proteasomal degradation. Proc Am Thorac Soc 2: A755 (Abstr.)
100. Failla M, To Y, Ito M, Adcock IM, Barnes PJ, Ito K. (2007) Oxidative stress-induced PI3-kinase activation reduces HDAC activity and is inhibited by theophylline. Proc Am Thorac Soc 2: A45 (Abstr.)
101. Tsai LH, Haggarty SJ, Kim D (2010) Activation of histone deaetylases 1 (hdac1) protects against dna damage and increases neuronal survival. Wolf Greenfield & Sacks PC, Boston MA, US Applicaton #20100075926, USPTO Class 514 82.
102. Bhuiyan MMR, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S, Sarkar FH. (2006) Down-regulation of androgen receptor by 3,3-diindolylmethane contributes to inhibition of cell proliferation and induction of apooptosis in both hormone-sensitive LNCaP and insensitive C4-2B Prosate Cancer Cells. Cancer Res 66: 10064-10072.
103. Kong D, Banerjee S, Huang W, Li Y, Wang Z, Kim HRC, Sarkar FH. (2008) Mammalian target of rapamycin repression by 3,3-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-d-over-expressing PC3 cells. Cancer Res 68: 1927-1934.
104. Li Y, Li X, Guo B. (2010) Chemopreventive agent 3,3-diinolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res 70: 646-654.